Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus SODIUM PERTECHNETATE TC 99M.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus SODIUM PERTECHNETATE TC 99M.
CIS-MDP vs SODIUM PERTECHNETATE TC 99M
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Sodium pertechnetate Tc-99m is a radiopharmaceutical that emits gamma rays (140 keV). The pertechnetate anion (TcO4−) is taken up by the thyroid gland via the sodium-iodide symporter (NIS) and also distributes in salivary glands, gastric mucosa, and choroid plexus. It acts as a diagnostic imaging agent by localizing in tissues via active transport or diffusion, allowing external detection with gamma cameras.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
370-1110 MBq (10-30 mCi) intravenously as a single dose for brain imaging; 370-740 MBq (10-20 mCi) intravenously for thyroid imaging; 185-370 MBq (5-10 mCi) intravenously for salivary gland imaging.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life: approximately 6 hours. Clinical context: Allows for imaging up to several hours post-injection; clearance is delayed in renal impairment.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Renal: approximately 30-50% of the injected dose is excreted in urine within 24 hours. The remainder is eliminated via the hepatobiliary system into feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical